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ABSTRACT
The acquisition of the capacity to invade surrounding tissues confers a
more malignant phenotype to tumor cells and is necessary for the estab-
lishment of metastases. The understanding of the molecular mechanisms
underlying cell invasion in human solid tumors such as colorectal cancers
could provide not only more sensitive prognostic analyses but also novel
molecular targets for cancer therapy.
We report in this article that K ion channels belonging to the HERG
family are important determinants for the acquisition of an invasive
phenotype in colorectal cancers. The herg1 gene and HERG1 protein are
expressed in many colon cancer cell lines, and the activity of HERG
channels modulates colon cancer cell invasiveness. Moreover, the amount
of HERG1 protein expressed on the plasma membrane is directly related
to the invasive phenotype of colon cancer cells.
Finally, both the herg1 gene and HERG1 protein were expressed in a
high percentage of primary human colorectal cancers, with the highest
incidence occurring in metastatic cancers, whereas no expression could be
detected either in normal colonic mucosa or in adenomas.
INTRODUCTION
Cancer development is a multistep process, which includes not only
alterations in cell growth and survival, but also the acquisition of the
ability to invade surrounding tissues (1, 2). The final step of tumor
progression is the establishment of metastases, which represent the
major hindrance to cancer therapy (1, 2).
It has been proposed that the altered setting of the plasma mem-
brane electric potential (Vrest) of cancer cells can contribute to tumor
growth (3). Our studies have shown that Vrest in tumor cells can often
be modulated by the activity of K channels, encoded by the human
ether a-go`-go` related gene (herg; Ref. 4). The corresponding current,
IHERG, can contribute to driving the Vrest of tumor cells to more
depolarized values, due to the peculiar biophysical properties of IHERG
(5). Both the herg gene and HERG protein are indeed expressed in
tumor cell lines of differing histogenesis (4), as well as in primary
human cancers, such as endometrial adenocarcinomas (6), acute my-
eloid leukemias (7), and lymphoid leukemias (8). In leukemia (7, 8)
and neuroblastoma cells (5, 9), HERG channel activity modulates the
progression through the mitotic cycle; in these cells an alternative
transcript of the herg1 gene, herg1b, was cloned and shown to be
mainly expressed during the S phase of the cell cycle (9). On the
whole, data gathered thus far suggest that HERG channels may play
a prominent role in the control of tumor cell proliferation (7–9) and
apoptosis (10). On the other hand, direct proof for the role of HERG
channels in the regulation of tumor progression is lacking thus far,
except for the demonstration of a functional association of HERG
channels with integrin receptors (11, 12), which are the adhesion
receptors mainly involved in tumor cell migration and invasion (1, 2).
Colorectal cancer is the third leading cause of cancer death world-
wide (13), and the genetic steps involving mutations of suppressor
genes (14–16) are well known. On the other hand, there is a paucity
of molecular predictive indicators for regional disease invasion and
metastasis in this type of cancer.
On the basis of these premises, we studied the expression of HERG
channels and their role in the process of tumor progression in colo-
rectal cancers.
MATERIALS AND METHODS
Cell Culture. Human colon cancer cell lines (H630, HCT8, DLD1, and
HCT116) were cultured in RPMI 1640 containing 10% FCS and antibiotics
(penicillin 100 units/ml and streptomycin 100 g/ml). H630 cell clones were
isolated by limiting dilution. HEK 293 cells were stably transfected with the herg1
gene in the pCDNA3.1() vector (Invitrogen; HEK-HERG1 cells) or with the
empty vector (HEK-MOCK). Cells were routinely tested for HERG channel
expression by RNase protection assay, Western Blot, and patch clamp (see below).
Tissue Collection. Tissue specimens of paired neoplastic and normal mu-
cosa (collected at least at 10 cm distant from the primary tumor), were obtained
from surgical operations in patients suffering from colorectal cancers, after
informed written consent was obtained. Patients were all treated at the First
Division of General Surgery and Transplantation of Careggi Hospital, Firenze.
Patients affected by viral hepatitis or who underwent previous combined
neoadjuvant radiochemotherapy were excluded from data collection. Clinico-
pathological characteristics of patients enrolled in the study (evaluated by
L. M.) are reported in Table 1. Eleven polyps obtained from both colonosco-
pies and surgical operations were also examined. Tissue samples were taken in
the operating room and immediately frozen or fixed in 4% formaldehyde in
PBS in preparation for being embedded in paraffin. Particular care was taken
in sampling normal mucosa to avoid the presence of muscolaris propria, which
has been demonstrated to express the herg1 gene and HERG1 protein (17).
Cell Invasion Assay. Cell invasion was studied essentially as reported in
(18). Two hundred l of cell suspension were inoculated into the upper well
of a Boyden chamber in the presence or in the absence of the specific IHERG
inhibitor Way 123,398 (Way; a kind gift from Dr. Walter Spinelli at Wyeth-
Ayerst Research, Princeton, NJ) at 40 M final concentration. After different
times of incubation at 37°C, the migrated cells that remained trapped on the
lower surface of the filter were fixed, stained with Diff-Quik stain kit (Dade
Behering), and counted.
RNase Protection Assay. RNase protection assay was performed essen-
tially as reported in Crociani et al. (9), using the herg probe, which is capable
of recognizing both the herg1 and the herg1b genes.
Reverse Transcription and PCR. Reverse transcription-PCR for the
herg1 and gapdh genes was performed as reported previously (7, 8).
Production of the Anti-HERG1 COOH-Terminus Antibody. The
cDNA encoding amino acids 1106–1158 of the HERG1 protein was PCR
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amplified (5 primer: GTCGACGGACTCGCTTTCTCAGGT, SalI site itali-
cized; 3 primer: GCGGCCGCACTGCCCGGGT, NotI site italicized) and
cloned in frame with GST gene into pGEX 4T-2 vector (Pharmacia). Rabbit
immunization, collection, and testing of the serum were performed as reported
for the anti-HERG NH2 terminus antibody (8).
Protein Extraction and Western Blot. Membrane protein extraction from
HEK 293, H630, and HCT8 cells was performed as described previously (9).
Tissues from both cancerous tissues and the corresponding mucosa were lysed
by homogenizing samples in cold Tris HCl (pH 7.4) 50 mM, NaCl 125 mM,
NP40 0.1%, EDTA 5 mM, and NaF 0.1 M, plus a complete protease inhibitors
mixture (Roche). Western blots were obtained as reported (9), loading different
amounts of protein extracts (15 g for HEK-HERG1 cells, 60 g for H630,
HCT116, and HCT8 cells; and 60 g for neoplastic and normal tissues), and
membranes were decorated with the anti-HERG1 COOH-terminus antibody
(see above) at 1:1000 dilution. In some experiments the antibody was prein-
cubated with an excess of the antigenic peptide used for immunization.
Immunohistochemistry (IHC). IHC was performed on 7-m sections
mounted on polylysine-coated slides. After dewaxing and blocking endoge-
nous peroxidases, sections were treated with proteinase K (Roche; 5 g/ml in
PBS) and UltraVBlock solution (LabVision) containing 0.1% Triton X100,
and then incubated with the primary antibody (anti-HERG1 COOH-terminus
antibody; see above) diluted 1:100 in PBS-UltraVBlock (10:1 v/v) overnight at
4°C. Immunostaining was carried out using a commercially available kit
(PicTure Plus kit; Zymed). For the negative control preimmune serum replac-
ing the primary antibody was used.
Patch Clamp Recordings. Patch-clamp recordings were performed on
colon carcinoma cell lines at room temperature with an Axopatch 1-D ampli-
fier (Axon Instruments, Foster City, CA), as reported previously (12). The
antiarrhythmic drug Way was used at a 1 M concentration. For data acqui-
sition and analysis, the pClamp hardware and software (Axon Instruments) and
Origin (Microcal Software, Northampton, MA) were routinely used.
RESULTS AND DISCUSSION
The herg1 Gene and HERG1 Protein Are Highly Expressed in
Colon Carcinoma Cell Lines. herg1 gene expression was tested by
RNase protection assay in various human colon cancer cell lines
(DLD1, HCT8, HCT116, and H630) as performed previously in
various cancer cell lines (9). As shown in Fig. 1A, the herg1 gene was
expressed in all of the cell lines examined although at different
degrees (see Fig. 1, inset). In particular, HCT116 and H630 cells
expressed herg1 at the highest level, whereas HCT8 cells expressed it
at the lowest level. No expression of the alternative transcript herg1b
could be detected in colon cancer cell lines, whereas it was present in
the heart, as expected (9, 19).
The above results were also confirmed by Western blots with a
novel anti-HERG1 COOH-terminus antibody developed in our labo-
ratory. The immunoreactivity and specificity of the antibody was first
tested on proteins extracted from herg1-transfected HEK 293 cells
(Fig. 1B). The protein pattern was the same as that obtained with
commercial anti-COOH-terminus antibodies (9). When tested on co-
lon cancer cells (Fig. 1C), the antibody recognized the HERG1 protein
in its immature (Mr 135,000) and mature (Mr 155,000) forms (9).
No HERG1B protein was detectable. These experiments also con-
firmed that H630 and HCT116 cells express the HERG1 protein at
higher levels compared with HCT8 cells.
A typical IHERG could also be recorded in colon cancer cells: a
representative example is shown in Fig. 1D. The inward current that
was observed in high potassium extracellular solution (Fig. 1D), was
completely blocked by Way, specific inhibitor of IHERG (Fig. 1D).
The current resulting from the subtraction of traces obtained in the
presence and absence of Way (Fig. 1D) displays the typical features
of the IHERG described previously in many tumor cell lines (4, 5).
The Activity of HERG Channels Regulates Cell Invasion in
Colon Cancer Cells. The role of HERG channels in the invasiveness
of colon cancer cells was first studied by analyzing the effect of
HERG channel activity on cell migration through Matrigel-coated
porous membranes inserted into Boyden chambers. Experiments were
performed in the absence or in the presence of the HERG current
inhibitor Way (5, 9). As shown in Fig. 2 the addition of Way
significantly reduced cell migration in H630, HCT116, and, although
to a lesser extent, HCT8 cells; on the other hand, migration of HEK
293 cells, an epithelial cell line devoid of HERG channels, was
unaffected by Way addition (Ref. 20; see also Fig. 1B).
These data show that HERG activity is an important factor regu-
lating cell invasion of colon cancer cells. Moreover, data on Fig. 2
show a trend of correlation between the amount of HERG1 expressed
and the invasion potential in the various cell lines, suggesting that the
amount of HERG1 protein could somehow modulate the invasive
capacity of colon cancer cells.
The Amount of HERG1 Protein Correlates with the Invasion
Capacity of Colon Cancer Cells. Because the cells in Fig. 2 were
derived from potentially divergent sources (and may have many
genetic differences in addition to their HERG expression), to test
whether HERG1 expression could be specifically responsible for the
difference in invasive capacity in colonic cancer cells, we developed
a set of cell lines with various levels of HERG expression from a
homogeneous background. Different clones from the H630 cell line
were selected to obtain cells displaying low and high HERG expres-
sion. Cloning by limiting dilution yielded 20 clones, with roughly
the same amount of clones with low and high HERG expression. Two
clones were chosen displaying both the herg1 mRNA (Fig. 3A) and
the HERG1 protein (Fig. 3B) at high (clone 3C8) and low (clone 3D3)
levels, respectively. A correlation between the amount of HERG1
protein and the average amount of IHERG expressed in the cell pop-
ulation was confirmed (data not shown). When analyzed regarding
their migration through Matrigel, the 3C8 clone displayed an invasion
capacity almost three times higher than the 3D3 clone (Fig. 3C, black
bars). The invasive phenotype of the 3C8 clone reverted to the less
invasive phenotype (associated with low HERG activity) when the
Table 1 Demographic characteristics and histopathological parameters
No. of patients Percentage
Sex
M 34 57%
F 26 43%
Localization
Right 20 33%
Transverse 7 12%
Left 12 20%
Rectum 21 35%
Grading
G1 4 7%
G2 51 85%
not determined 5 8%
Mucin
Yes 22 37%
No 38 63%
Tumor-Node-Metastasis stage
1 10 17%
2 20 33%
3 18 30%
4 12 20%
Metastases
Yes 8 13%
No 52 87%
Dukes’
A 10 17%
B 20 33%
C 22 37%
D 8 13%
Jass
I 2 3%
II 10 17%
III 21 36%
IV 26 44%
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activity of the HERG channels was specifically blocked by Way
addition (Fig. 3C, white bars). The difference in both HERG expres-
sion and invasion capacity of the two clones was maintained between
4 and 20 passages, and after freezing and thawing. On the other hand
no difference in the growth in soft agar of the two clones was ever
detected (10.8  2.9 large colonies/microscopic field in 3D3 versus
11.0  7.0 in 3C8).
The relationship between HERG1 expression and invasion capacity
was confirmed by experiments on HEK 293 cells transfected with
either a herg1-containing plasmid (HEK-HERG1) or an empty vector
(HEK-MOCK). As shown in Fig. 4, cell migration through Matrigel
was strongly increased in HEK 293 cells overexpressing herg1 as
compared with HEK-MOCK. Here again cell invasion turned out to
depend on HERG channel activity (see the inhibitory effect of Way on
HEK-HERG1 cells reported in Fig. 4, inset). It is worth noting that
Way addition did not alter cell invasion capacity in HEK-MOCK cells
(data not shown), as stated above for HEK 293 wild-type cells.
herg1 Gene and HERG1 Protein Are Expressed in Primary
Human Colorectal Cancers, with a Higher Incidence in Metastatic
Cancers. To assess the pathophysiological significance in vivo of the
results gathered thus far, we investigated whether HERG channels
were expressed also in primary colorectal cancers, and if a correlation
existed between such expression and the acquisition of an invasive
and metastatic phenotype.
The expression of the herg1 gene and protein was determined in a
set of primary colorectal adenocarcinomas (Adk) displaying different
anatomical localizations and tumor grades (see Table 1). For each
tumor, a sample of the corresponding normal colonic mucosa (M) was
Fig. 1. herg1 gene and HERG1 protein expres-
sion in human colon carcinoma cell lines. A, herg1
gene expression. RNase protection assay was per-
formed on RNA extracted from DLD1, HCT8,
HCT116, and H630 colon carcinoma cells, and
probed with the herg1 probe, which is able to
discriminate between herg1 and herg1b as de-
scribed in (9). Human heart RNA was used as a
control; human cyclophilin (hcyc; Ambion) was
used as an internal control and yeast tRNA as a
negative control to test for probe self protection
bands. Exposure was for 1 day. herg1, herg1b, and
hcyc protected bands are indicated by arrows. In-
set, densitometric analysis of herg1 expression;
signals of the herg1 protected bands were normal-
ized using the corresponding values of cyclophilin,
and the value obtained in HCT116 cells was nor-
malized to 1. B, HERG1 protein expression in HEK
293 cells; Western Blots were performed on pro-
teins extracted from HEK 293 cells transfected
with a herg1 construct (HEK-HERG1; Lane 1) and
from HEK 293 wild-type cells (Lane 2), and were
then probed with the anti COOH-terminus antibody
as described in “Materials and Methods.” Lane 3
shows the result of a Western blot performed on
HEK-HERG1 using the antibody preincubated with
an excess of antigenic protein. C, HERG1 protein
expression in colon carcinoma cells lines. A West-
ern blot was performed as in B. Lane 1: HEK-
HERG1; Lane 2: H630; Lane 3: HCT8; Lane 4:
HCT116. D, HERG current traces obtained in
H630 colon carcinoma cell line: IHERG was meas-
ured at [K]o  40 mM, as the peak current elicited
at 120 mV, after 15 s preconditioning at 0 mV.
Top, protocol used in the experiment shown. (D)
traces obtained in control conditions; (D) traces
obtained after perfusion of the cell examined with 1
M Way; (D) traces obtained after subctracting
traces of D from traces of D and revealing the net
IHERG. Note the different X-axis scale in D.
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also included in the study; some adenomas (Ad) obtained either from
surgical operations or endoscopies were also studied. All of the
samples were analyzed for herg1 gene expression by reverse tran-
scription-PCR, and HERG1 expression by Western blot and IHC.
As shown in Fig. 5A the PCR band related to the herg1 transcript
was easily detectable in representative samples belonging to Adk,
whereas a corresponding band was undetectable both in M and Ad.
This result was confirmed by Western blot experiments: a typical
experiment is reported in Fig. 5B. The molecular weight of the band
was Mr 145,000, as described in human hearts by Pond et al. (21).
Here again HERG1B was not expressed.
A complete IHC analysis of HERG1 protein expression on paraffin
sections of all of the cases collected was performed. As shown in Fig.
6 no specific signal relative to HERG1 protein was evident either in
epithelial tubules of M (Fig. 6A) or in Ad (Fig. 6B); on the other hand,
Adk samples were positive for HERG1 (Fig. 6C), showing a specific
labeling of epithelial cells. A focal pattern of staining was always
Fig. 2. Role of HERG1 in invasion of colon carcinoma cells, effect of Way. Colon
carcinoma cell lines (H630, HCT116, and HCT8) and HEK 293 cells were seeded onto
Matrigel-coated porous membranes inserted into Boyden chambers, in RPMI 1640 con-
taining 250 g/ml BSA, and left to migrate for 6 h (H630, HCT 116, and HCT8) or 16 h
(HEK 293) at 37°C in a humidified atmosphere containing 5% CO2. The specific HERG
inhibitor Way was added at time zero to the cell suspension at 40 M final concentration;
this concentration has been used previously to impair leukemia and neuroblastoma cell
proliferation (7, 9). Values are reported as the total number of migrated cells, and
represent means of three separate experiments performed, each carried out in triplicate;
bars, SE. * P 	 0.005 Student’s t test.
Fig. 3. Relationship between HERG1 expression and invasion capacity in colon
carcinoma cells. A and B, selection of different clones from H630 cells with high and low
herg1 gene (A) and HERG1 protein (B) expression. Different clones from H630 cells were
isolated by limiting dilution, and the amount of herg1 gene and HERG1 protein expression
was analyzed by RNase protection assay and Western blot, as reported in the legend to
Fig. 1. Two clones with high (3C8) and low (3D3) expression of both the gene and the
protein are reported. C, invasion capacity of H630 cell clones expressing HERG1 at
different levels. The invasion potential of 3C8 and 3D3 clones was studied by measuring
the number of migrated cells as reported in the legend to Fig. 2, except that cells were left
to migrate for 3 h in the absence (f) or in the presence () of the specific HERG inhibitor
Way. Data represent the mean of four experiments, each carried out in triplicate; bars,
SE. * P 	 0.005, Student’s t test.
Fig. 4. Effect of HERG1 overexpression on invasion by HEK 293 cells. HEK 293 cells
were stably transfected with herg1-containing (HEK-HERG1) or an empty pCDNA3.1
vector (Mock transfected, see “Materials and Methods”). Cell invasion was studied as
reported in the legend to Fig. 2 except that the cells were left to migrate for 12 h. Values
are means of four separate experiments each carried out in triplicate; bars, SE.
* P	 0.005, Student’s t test. Inset, the effect of Way addition on HEK-HERG1 migration.
Fig. 5. herg1 gene and HERG1 protein expression in primary human colorectal
cancers. A, herg1 gene expression. Reverse transcription-PCR relative to herg1 and gapdh
genes from colorectal cancer cDNA was performed as reported previously (10). The FLG
29.1 cell line was used as the positive control for herg1 expression; ADK, adenocarcinoma
sample; AD, adenoma sample; M, normal colonic mucosa sample of the two ADK
reported in the figure; C: no DNA, no RNA sample. B, HERG1 protein expression in
neoplastic and normal tissue. A Western blot was performed on primary human tissue as
reported in “Materials and Methods” using the anti-HERG 1 antibody produced in our
laboratory. ADK, adenocarcinoma sample; M, normal colonic mucosa sample; ADK
(antigen excess), adenocarcinoma sample probed with the anti-HERG 1 antibody prein-
cubated with an excess of antigenic protein. Note that no band below the HERG1 band (in
the expected position of HERG1B) is detectable.
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detected in positive Adk samples. Control experiments performed
with preimmune serum resulted in no positive staining (a represent-
ative example of an Adk sample is shown in Fig. 6C, inset).
The comparison of data obtained by reverse transcription-PCR and
IHC resulted in essentially concordant results: a quantitative analysis
of all of the results obtained is reported in Fig. 6D and shows that the
HERG1 protein was never expressed in M (60 of 60 specimens
examined), but was expressed in 9% (1 of 11) Ad, and in 75% (39 of
52 cases) of nonmetastatic Adk (Dukes’ A-C). Metastatic (Dukes’ D)
Adk turned out to be 100% positive for HERG1 protein expression (8
of 8). Hepatic and peritoneal metastases (Fig. 6E) not only were
positive, but also displayed a widespread and homogeneous staining
(rather than showing a focal pattern of HERG1 expression).
CONCLUSIONS
We studied the role of HERG channels in colon cancer cell inva-
siveness, and showed that: (a) almost all of the colon cancer cell lines
express the herg1 gene and HERG1 protein; (b) the activity of HERG
channels regulates cell invasiveness in many colon cancer cell lines;
(c) the amount of HERG1 protein correlates with a more invasive
phenotype of colon cancer cells; and (d) whereas no expression of
HERG channels was detected in normal human colonic mucosa and
adenomas, a high percentage of primary colorectal cancers expressed
the HERG channel, with a higher incidence in metastatic cancers.
Therefore, these results provide evidence that K channels belonging
to the HERG family are involved in the establishment of an invasive
phenotype in colorectal cancer cells both in vitro and in vivo.
Data reported in this article point to the conclusion that the role of
HERG channels in primary solid tumors like colorectal cancers could
be that of determining the acquisition of features leading to the
establishment of a true invasive and metastatic cancer. Therefore, the
immunohistochemical detection of HERG1 protein could represent an
independent prognostic factor in the future.
On the whole, voltage-dependent K channels, especially those be-
longing to the HERG subfamily, could represent oncogenic products,
because they promote cell proliferation and survival (7–10), and contrib-
ute to conferring a malignant, invasive phenotype to cancer cells.
Targeted therapies promise to revolutionize the care of cancer
patients: HERG channels and their inhibitors could be used not only
as novel prognostic factors but also as novel molecular targets in the
future.
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Fig. 6. Immunohistochemical detection of
HERG1 protein on normal and neoplastic colorectal
tissues. Immunohistochemical detection of HERG1
protein on paraffin-embedded normal and neoplastic
human colorectal tissues was performed as reported
in “Materials and Methods,” using the anti-HERG 1
polyclonal antibody reported above, and used at
1:100 dilution. A, normal colonic mucosa, normal
epithelial tubules resulted in no HERG-specific stain-
ing. B, colonic adenoma, with no HERG-staining in
tubular structures. C, adenocarcinoma of the rectum.
Note neoplastic epithelial cells showing an intense
and focal immunostaining; in the inset is reported a
neoplastic specimen decorated with preimmune se-
rum diluted 1:50. D, histogram showing data relative
to all of the specimens collected (see Table 1). Sixty
samples of adenocarcinoma (ADK) and paired co-
lonic mucosa (M) were examined: 8 ADK were clas-
sified as Dukes’ D (ADK Mtx), whereas the others
belonged to Dukes’ groups A–C. Eleven adenomas
(AD) were also examined in this study. E, adenocar-
cinoma metastasis to the liver. Almost all of the
metastatic epithelial cells show an intense immuno-
staining, without the focal pattern displayed by pri-
mary tumors (see C). In this case the anti-HERG1
antibody used was diluted 1:200.
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